BioStem Technologies Files S-1 Registration Statement with SEC
BioStem Technologies, Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on October 2, 2026 (File No. 0001658678, 11 MB). The filing initiates its U.S. IPO process and reflects standard disclosure requirements for pre-revenue biotech firms.
51CFO view：The S-1 requires precise clinical-stage cost allocation, stock-based compensation amortization, collaborative revenue allocation (ASC 606), and quantified FDA risk disclosure. CFOs must lead SEC-compliant biotech financial systems and coordinate PCAOB audit readiness.
BioStem Technologies, Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on October 2, 2026 (File No. 0001658678, 11 MB). The filing initiates its U.S. IPO process and reflects standard disclosure requirements for pre-revenue biotech firms.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →